POS0167 SECONDARY PREVENTION OF VERTEBRAL FRACTURES IN REAL PRACTICE

Background: Vertebral fractures increases the risk of new and deaths. There are different antiresorptive medications to prevent a secondary fracture, as bisphosphonates, teriparatide or denosumab, but little is known about effects fracture appearance in real life. Objectives: To evaluate vertebral depending on treatment used for prevention. Methods: We conducted prospective descriptive study patients with first diagnosis from 2010 2017 assessed subsequent finding fractures. selected at least 3 years prevention drugs sequential (anabolic followed by, least, 1 year drugs), excluded those who experienced within 6 months treatment. Results: A total 400 were an initial base 1018 patients. The average age onset was 69.7 years, 84% female 16% 38.5% suffered dorsal fractures, 33.75% lumbar 27.75% dorsolumbar classified strategies according therapeutic options, we can see Table 1. analysed association between corrected by sex its location. No found. also performed multivariate Bayesian model logistic regression, order analyze factors pharmacologic option statistically significant differences observed treatments their efficacy However, there tendency smaller occurrence undergoing On other hand, similar results denosumab oral observing somewhat worse data zoledronate (figure 1), probably due under showed high osteoporotic prognosis. Pharmacologic Patients (%) New Denosumab 192 (48%) 10 (5.21%) Teriparatide (up 2 years) + (at year) 86 (21.5%) 0 (0%) Oral bisphosphonate (alendronate, risedronate ibandronate) 58 (14.5%) (5.17%) Zoledronate 33 (8.25%) 4 (12.12%) 28 (7%) (7.14%) (0,75%) (0%). Conclusion: options terms observed. Disclosure Interests: None declared